Abstract: Poster Presentations |

Additive Effects of Montelukast on Bronchial Hyperresponsiveness to MCh and LTE4 Urine Levels in Mild-persistent Atopic Asthmatics Assuming ICS FREE TO VIEW

Silvia Tognella, MD; Claudio Micheletto, MD; Maria P. Visconti, Biologist; Roberto W. Dal Negro, MD*
Author and Funding Information

Bussolengo General Hospital, Bussolengo, Italy


Chest. 2004;126(4_MeetingAbstracts):814S. doi:10.1378/chest.126.4_MeetingAbstracts.814S-b
Text Size: A A A
Published online


PURPOSE:  Inhaled corticosteroids (ICS) are regarded as the first-line treatment in patients with persistent asthma, resulting lung function, bronchial hyperresponsiveness and eosinophilic inflammation significantly improved. Nonetheless, many patients receiving ICS continue to experience asthma symptoms, and both the synthesis and the release of cys-leucotrienes (LTs) are not inhibited completely. Montelukast, a selective cys-LT1 receptor antagonist, has been found to reduce airway eosinophilic inflammation in patient with asthma, and it would then provide additional benefit for symptomatic patients already receiving ICS. Aim: to assess and compare the 6-week efficacy of ICS alone and of ICS+Montelukast on bronchial hyperresponsiveness to MCh and on the LTE4 urine levels in mild-persistent asthma.

METHODS:  After informed consent, 18 mild-persistent atopic (prick test positive for inhalants) asthmatics (18-62y; mean basal FEV1=103.2%pred±15.4sd; mean PD20FEV1 to MCh=89.8mcg±102.6sd) were randomized. Nine subjects received only Fluticasone p. 250mcg o.d. (group FP), and the remaining 9 Fluticasone p. 250mcg o.d. plus Montelukast 10mg o.d. (FP+M), for 6 weeks according to a double-dummy, double-blind design. PD20 FEV1 to MCh and LTE4 urinary levels were assessed in bsln and at the end of treatments. Urine were collected in the morning and processed by an immunoenzimatic method (Cayman Chemical, Mi, USA). Statistics: t test vs basal and between treatments; p< 0.05 accepted.

RESULTS:  In tab. 1.

CONCLUSION:  1) unlike ICS, only the addition of Montelukast enables a substantial decrease of urinary LTE4; 2) the LTs-mediated inflammation confirms its relevant role in atopic asthma.

CLINICAL IMPLICATIONS:  Montelukast provides a consistent additional control on bronchial hyperresponsiveness when added to ICS in mild persistent asthma. Tab,1FEV1 (%pred)MCh (mcg)LTE4 g/ml)FP basal95.1±8.261.2±70.1488.1±290.3FP+M basal98.5±9.1118.5±125.1430.3±288.1FP 6 wks103.2±15.4395.7±109.1*366.6±278.4FP+M6 wks101.2±11.4638.7±155.3§^179.7±126.1°*

p<0.001 vs FPbasal;


p<0.001 vs FP+M basal;


p<0.002 vs FP 6 weeks;

DISCLOSURE:  R.W. Dal Negro, None.

Wednesday, October 27, 2004

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543